Investors

Press Releases

Press Releases

October 21, 2020
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
REDWOOD CITY, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the publication of results from the multicenter, randomized, double-blind,
June 3, 2020
Allakos Initiates Patient Recruitment for AK002 Registrational Studies
-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --  -- Top-line safety and efficacy results from both studies expected in the second half of 2021 -- REDWOOD CITY, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- Allakos Inc.
May 11, 2020
Allakos Reports First Quarter 2020 Financial Results
REDWOOD CITY, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2020.
March 24, 2020
Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies
Phase 3 study of antolimab for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis) Phase 2/3 study of antolimab for the treatment of eosinophilic esophagitis Phase 1 study of subcutaneously administered antolimab in healthy
Displaying 1 - 10 of 12


(Common Stock)


October 15, 2020 3:29 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.